News/ Pfizer/ Rare diseases/ UK & Europe Spark and Pfizer’s haemophilia gene therapy gets European PRIME status Marco Ricci cell and gene therapy, gene therapy, haemophilia B, Priority Medicines programme, Spark Therapeutics 0 Comment Decision based on promising data from ongoing phase 1/2 trial. Share X Spark and Pfizer’s haemophilia gene therapy gets European PRIME status https://pharmaphorum.com/news/spark-pfizers-haemophilia-b-gene-therapy-gets-priority-medicines-access/